Trade GHRS anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
GH Research PLC (GHRS) is trading at US$27.94, down 2.48% today as of Aug 28, 16:00 EDT. The company has a market capitalisation of US$1.94B. Over the past 52 weeks, GHRS has traded between US$11.83 and US$31.44. On Syfe you can trade GHRS with $0 commission and add it to your watchlist.
| Previous close | US$28.65 |
|---|---|
| Market cap | US$1.94B |
| 52-week range | US$11.83 – US$31.44 |
| Volume | 117.63K |
| Exchange | US |
Add to Watchlist
Set Price Alert
GH Research PLC
GH Research Plc is a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients with psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.
Year: 2021
Wells Fargo Initiates GH Research at Overweight With $44 Price Target
Jul 27, 12:12 PM · MT Newswires
GH Research's Q1 Net Loss Widens
May 14, 11:42 AM · MT Newswires
--Earnings Flash (GHRS) GH Research Posts Q1 Loss $0.31 a Share, vs. FactSet Est of $0.29 Loss
May 14, 11:22 AM · MT Newswires
FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain
Apr 24, 2:19 PM · MT Newswires
Sector Update: Health Care Stocks Fall Late Afternoon
Apr 20, 7:55 PM · MT Newswires
GH Research PLC (GHRS) stock is trading at US$27.94, -2.48% from the previous close of US$28.65.
The market cap for GH Research PLC (GHRS) stock is approximately US$1.94B.
The 52-week high for GH Research PLC (GHRS) stock is US$31.44.
The 52-week low for GH Research PLC (GHRS) stock is US$11.83.
GH Research PLC (GHRS) does not currently pay a dividend.
Stay on top of GHRS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
